Share
An excess of growth hormone in infancy leads to the rare yet confounding phenomenon of X-linked acrogigantism, which is known to be resistant to conventional pituitary tumor treatments in the pediatric population. However, new data suggests that pegvisomant could not only be a treatment option for these patients, but it could also improve quality-of-life measures....
Share
Racial and gender disparities in healthcare begin early — including among children who could benefit from treatment for short stature. New research seems to show that white children — especially boys — are offered growth hormone stimulation tests at a significantly higher rate than girls or Black and Hispanic children. The racial, ethnic, and gender...
Share
As the desire for a less frequently administered growth hormone treatment intensifies, clinicians are looking to researchers for the latest data on safety and efficacy. Luckily, as more studies are undertaken patients and clinicians may soon have a wealth of options. Since 1985, children with growth hormone deficiency (GHD) have been prescribed somatropin – recombinant...
Share
ENDO 2022 saw the presentation of positive clinical data from the open-label extensions (OLEs) of two of the Phase 3 trials of oral octreotide for patients with acromegaly. Amryt is marketing the drug as Mycapssa. Data presented in a late-breaking poster presentation of the 2nd year of the OLE of OPTIMAL (NCT03252353), a randomized, double-blind...
Share
What Is the Role of “Growth Hormone” When You Have Stopped Growing? Growth hormone clearly plays a key role in development during youth, but research in adults implicates it as an agent in cellular aging processes. Shlomo Melmed, MD, ChB, the first recipient of the Transatlantic Alliance Award, co-sponsored by the Endocrine Society and the...
Share
Growth hormone deficiency (GHD) among adults is associated with greater medical costs and an increased rate of other health conditions compared with those without GHD, according to industry-sponsored research presented at ENDO 2022 in Atlanta. Researchers led by Alden Smith, PharmD, Global Head of Health Economics and Outcomes Research at Ascendis Pharma in Palo Alto,...
Share
In November, the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for Ascendis Pharma’s lonapegsomatropin (TransCon hGH), a long-acting once-weekly, transiently pegylated somatropin that in the body releases somatropin, indicated for growth failure in children and adolescents aged from 3 years...
Share
Rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) space in the three major markets (3MM): the US, Germany, and Japan. These therapies are projected to capture more than 90% of market share in this region by 2030 due to their potential to improve patient convenience and...